---
title: "Vaxcyte names Luis Jodar as chief medical officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297953007.md"
description: "Vaxcyte has appointed Luis Jodar as its new chief medical officer, where he previously served as Pfizer's chief medical officer for vaccines and infectious diseases. Additionally, David McAvoy has joined the company as chief legal officer, bringing prior experience from Teva."
datetime: "2026-09-03T20:07:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297953007.md)
  - [en](https://longbridge.com/en/news/297953007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297953007.md)
generator: "portal-rs"
---

# Vaxcyte names Luis Jodar as chief medical officer

-   Vaxcyte named Luis Jodar as chief medical officer. \* Jodar previously served as Pfizer chief medical officer for vaccines and infectious diseases. \* David McAvoy joined as chief legal officer. \* McAvoy previously served as Teva chief legal officer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609031605PRIMZONEFULLFEED9821280) on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PCVX.US](https://longbridge.com/en/quote/PCVX.US.md)
- [VCYT.US](https://longbridge.com/en/quote/VCYT.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Vaxcyte Announces Commencement Of Proposed Public Offerings Of Common Stock, Pre-Funded Warrants And Convertible Senior Notes](https://longbridge.com/en/news/300969941.md)
- [BUZZ-Vaxcyte surges on pneumococcal vaccine late-stage trial success](https://longbridge.com/en/news/300919546.md)
- [Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil disposes of USD 127,561 in common shares](https://longbridge.com/en/news/300823923.md)
- [Vaxcyte prices USD 500 million convertible senior notes offering due 2032](https://longbridge.com/en/news/301093955.md)
- [Vaxcyte launches USD 500 million convertible senior notes offering due 2032](https://longbridge.com/en/news/300965255.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**